SPOTLIGHT -
EP. 1: Squamous Cell Carcinoma Treatment Options
EP. 2: Introduction: Advances and Issues in NSCLC
EP. 3: Best Practices in NSCLC Molecular Testing, Part I
EP. 4: Concurrent Versus Sequential Testing in NSCLC
EP. 5: Best Practices in NSCLC Molecular Testing, Part II
EP. 6: Molecular Testing and Actionable Targets in NSCLC
EP. 7: Rebiopsying and Molecular Testing in NSCLC
EP. 8: Selecting a Laboratory for Molecular Testing in NSCLC
EP. 9: Selecting Treatment for First- Line Non-Squamous NSCLC
EP. 10: Molecular Heterogeneity in Non-Small Cell Lung Cancer
EP. 11: Promising Emerging Classes of Therapies in NSCLC
EP. 12: Personalizing the Treatment of Lung Cancer
EP. 13: Access to Molecular Testing Therapy in NSCLC
EP. 14: Impact of EGFR Mutations on Treatment Decisions in NSCLC
EP. 15: The Cost-Effectiveness of Targeted Therapies in NSCLC
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
Dr Westin on Outcomes of the SOLAR Trial in RAS-Mutant Gynecological Malignances
